Advanced therapy medicinal products

A tissue-engineered advanced therapy medicinal product (ATMP) is:

A gene ATMP can be described as:

Which of following licensed ATMPs is NOT administered in a single dose?

In the UK, ATMPs are evaluated and authorised centrally by the:

Which of the following is the most commonly used ATMP in the UK?

The purpose of lymphodepletion prior to chimeric antigen receptor T-cell (CAR-T) therapy is to:

Where is up-to-date information on ATMP clinical trials located?

Spherox is an example of which class of ATMP?

Which of the following statements about autologous human corneal epithelial cells (Holoclar) is NOT true?

Which of the following statements about onasemnogene abeparvovec (Zolgensma) is NOT true?

What is the main reason for the lack of certainty in cost-effectiveness estimates of ATMPs?

Who undertakes horizon scanning for ATMPs?

Who has the ultimate responsibility for safety and governance of all medicines?

The National Institute for Health and Care Excellence recently recommended a new ATMP, even though its cost-effectiveness – at £120,000 per quality-adjusted life year gained – exceeded the usual threshold by about £100,000. Which of the following factors might have justified this decision?

There may be benefits to the NHS of using innovative payment methods for ATMPs. These could include risk-sharing schemes. Which of the following is a reason for needing alternative arrangements?